Welcome to our dedicated page for Reunion Neuroscience news (Ticker: REUN), a resource for investors and traders seeking the latest updates and insights on Reunion Neuroscience stock.
Reunion Neuroscience Inc. (REUN) is a forward-thinking company dedicated to advancing the field of neuroscience. Specializing in the development of innovative treatments for mental health disorders, Reunion Neuroscience is at the forefront of research and commercial application. The company is renowned for its groundbreaking RE200 series of molecules that aim to revolutionize therapeutic approaches to mental health.
The RE200 series includes preclinical compounds that exhibit enhanced receptor selectivity. These novel molecules are structurally similar to traditional psychedelics but specifically target the serotonin 2A receptor (5HT2A) while avoiding 5HT2B receptor agonism. This selective potency is expected to provide more effective treatments with fewer side effects, addressing additional therapeutic applications.
Founded with a commitment to improving mental health treatment, Reunion Neuroscience continually collaborates with research-intensive universities and industry partners. This approach helps ensure that the company's solutions meet emerging real-world challenges. One of its key products, Rizikon, is a cyber risk analysis and investment prioritization tool that assists organizations in identifying and mitigating their most significant vulnerabilities.
Reunion Neuroscience has a robust corporate structure and financial foundation, allowing it to focus on long-term growth and innovation. The company's recent clinical developments and corporate updates highlight its ongoing progress and dedication to its mission.
For more information, visit Reunion Neuroscience and follow the company on LinkedIn and Twitter. To stay updated with the latest news, opt-in at: Email Alerts.
Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) is hosting a corporate presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023. The presentation will detail the company's innovative therapeutic solutions for mental health conditions, focusing on its lead asset, RE104, a novel compound aimed at treating postpartum depression. RE104 is protected by U.S. Patent No. 11,292,765, which extends its protection until June 30, 2041. The conference is scheduled for April 25-26, 2023, at the Metro Toronto Convention Centre, with one-on-one meetings for institutional investors also available. Information on accessing the presentation webcast can be found on Reunion's website.
Reunion Neuroscience Inc. (NASDAQ: REUN) announced it received a notice from Nasdaq on April 19, 2023, indicating that its common shares did not meet the minimum bid price requirement of $1.00 per share over a 30-day period, ending April 18, 2023. The company has a compliance period of 180 days, until October 16, 2023, to regain compliance by maintaining a minimum bid price of at least $1.00 for ten consecutive business days. If compliance is not achieved, Reunion may be eligible for an additional 180-day period, but risks delisting if unable to cure the deficiency. No immediate impact on the company's business operations or share listing has been reported. Reunion is focused on developing innovative treatments for mental health conditions, including its lead asset, RE104, aimed at postpartum depression.
FAQ
What is the market cap of Reunion Neuroscience (REUN)?
What does Reunion Neuroscience Inc. specialize in?
What is the RE200 series?
How does the RE200 series differ from traditional psychedelics?
What is Rizikon?
How can I stay updated with Reunion Neuroscience's latest news?
Who are Reunion Neuroscience's key collaborators?
Where can I find more information about Reunion Neuroscience's products?
What recent achievements has Reunion Neuroscience made?
What is the corporate structure of Reunion Neuroscience?
Who can I contact for investor relations information?
